MedTrace Logo

The Maraviroc Central Nervous System (CNS) Study

NCT00982878 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-11-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.

Conditions

  • HIV Infections

Interventions

DRUG

Maraviroc

150mg twice daily

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Alan Winston · Imperial College London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-07-31
Completion
2011-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982878 on ClinicalTrials.gov